Source map — Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy?

Every domain this feed has drawn corroborated signal from. We store facts and short excerpts and link back to originals — never republished article bodies.